Literature DB >> 9360840

Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas.

B V Kallakury1, T P Brien, C V Lowry, P J Muraca, H A Fisher, R P Kaufman, J S Ross.   

Abstract

Telomerase adds a hexanucleotide telomeric sequence to the chromosomal ends during replication and is postulated to play a role in cellular senescence and immortalization. Thirty-four human prostate tissues (18 malignant; 16 benign) were analyzed for telomerase activity by a sensitive nonradioactive polymerase chain reaction (PCR)-based method using the TRAP-eze telomerase detection kit (Oncor, Inc., Gaithersburg, MD). Telomerase activity in the homogenized tissue extracts was correlated with tumor grade, pathologic stage, and DNA ploidy. Specimens that exhibited the 36 bp internal control band and a ladder of products with 6-base increments starting with 50 nucleotides were considered positive. Fourteen (78%) of 18 prostatic adenocarcinomas (PACs) and only 2 (13%) of 16 benign prostate tissues exhibited telomerase activity. Our results indicate that, in contrast to most benign prostate tissues, telomerase activity can be detected in the majority of PACs and appears to be independent of tumor grade, stage, or DNA ploidy. Telomerase expression is occasionally detected in benign prostatic tissues bordering PACs and may result from either the presence of undetected tumor foci in these stored specimens or the proliferative response of the benign elements to adjacent cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360840     DOI: 10.1097/00019606-199708000-00003

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  5 in total

1.  Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Authors:  Zhihu Ding; Chang-Jiun Wu; Mariela Jaskelioff; Elena Ivanova; Maria Kost-Alimova; Alexei Protopopov; Gerald C Chu; Guocan Wang; Xin Lu; Emma S Labrot; Jian Hu; Wei Wang; Yonghong Xiao; Hailei Zhang; Jianhua Zhang; Jingfang Zhang; Boyi Gan; Samuel R Perry; Shan Jiang; Liren Li; James W Horner; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Cell       Date:  2012-02-16       Impact factor: 41.582

Review 2.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance.

Authors:  R Montironi; R Mazzucchelli; F Algaba; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

3.  MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Authors:  Javier A Baena-Del Valle; Qizhi Zheng; David M Esopi; Michael Rubenstein; Gretchen K Hubbard; Maria C Moncaliano; Andrew Hruszkewycz; Ajay Vaghasia; Srinivasan Yegnasubramanian; Sarah J Wheelan; Alan K Meeker; Christopher M Heaphy; Mindy K Graham; Angelo M De Marzo
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

Review 4.  Biomarkers for prostate cancer.

Authors:  Eric Schiffer
Journal:  World J Urol       Date:  2007-08-10       Impact factor: 4.226

5.  A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.

Authors:  Pedro Castelo-Branco; Ricardo Leão; Tatiana Lipman; Brittany Campbell; Donghyun Lee; Aryeh Price; Cindy Zhang; Abolfazl Heidari; Derek Stephens; Stefan Boerno; Hugo Coelho; Ana Gomes; Celia Domingos; Joana D Apolonio; Georg Schäfer; Robert G Bristow; Michal R Schweiger; Robert Hamilton; Alexandre Zlotta; Arnaldo Figueiredo; Helmut Klocker; Holger Sültmann; Uri Tabori
Journal:  Oncotarget       Date:  2016-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.